Ginkgo Bioworks Holdings vs ARS Pharmaceuticals
Ginkgo Bioworks Holdings is the larger business, with $170m of revenue in fiscal 2025 against $84.3m for ARS Pharmaceuticals (2.0 times as much). ARS Pharmaceuticals grew faster (-5.5% against -25.1%). Ginkgo Bioworks Holdings kept more of each dollar of sales as profit: a net margin of -183.8% against -203.3%.
| Latest fiscal year | Ginkgo Bioworks HoldingsDNA, 2025 | ARS PharmaceuticalsSPRY, 2025 |
|---|---|---|
| Revenue | $170m | $84.3m |
| Revenue growth | -25.1% | -5.5% |
| Net income | −$313m | −$171m |
| Operating margin | — | — |
| Net margin | -183.8% | -203.3% |
| Return on equity | -51.1% | -92.3% |
| Free cash flow | −$179m | −$171m |
| Cash | $167m | $41.3m |
| Total debt | $0 | $96.4m |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 485 | 158 |
| Market value | $671m | $298m |
| Price vs our value range | — | — |
| Moat score | 12 (Weak) | — |
| Insider trades, 12 months | 0 buys, 24 sales | 0 buys, 5 sales |